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Cystinuria (OMIM 220100) is an inborn congenital disorder characterised by a defective cystine metabolism resulting
in the formation of cystine stones. Among the heterogeneous group of kidney stone diseases, cystinuria is the only
disorder which is exclusively caused by gene mutations. So far, two genes responsible for cystinuria have been
identified: SLC3A1 (chromosome 2p21) encodes the heavy subunit rBAT of a renal b0,+ transporter while SLC7A9
(chromosome 19q12) encodes its interacting light subunit b0,+AT. Mutations in SLC3A1 are generally associated with
an autosomal-recessive mode of inheritance whereas SLC7A9 variants result in a broad clinical variability even within
the same family. The detection rate for mutations in these genes is larger than 85%, but it is influenced by the
ethnic origin of a patient and the pathophysiological significance of the mutations. In addition to isolated cystinuria,
patients suffering from the hypotonia-cystinuria syndrome have been reported carrying deletions including at least
the SLC3A1 and the PREPL genes in 2p21. By extensive molecular screening studies in large cohort of patients a
broad spectrum of mutations could be identified, several of these variants were functionally analysed and thereby
allowed insights in the pathology of the disease as well as in the renal trafficking of cystine and the dibasic amino
acids. In our review we will summarize the current knowledge on the physiological and the genetic basis of
cystinuria as an inborn cause of kidney stones, and the application of this knowledge in genetic testing strategies.
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The incidence of kidney stone diseases has increased
over the last decades in the industrial countries to nearly
1.5% in 2000, about 5% of all women and 12% of men
will develop a kidney stone once in their life [1]. The
incidence in childhood is lower and has been estimated
to be approximately 0.15% (for review: [2]). Interestingly,
about 40% of children with kidney stones have a positive
familial history whereas urolithiasis in adults often
occurs sporadically.
In case of stone formation, the qualitative analysis is one
of the most important diagnostic measures: calcium and
oxalate are the main stone components in the European
population detectable in more than 75% of patients,
whereas phosphate, cystine, purine and other stones
are often rare (for review: [2]). Many lithogenic and
inhibitory factors are involved in the aetiology of stone
formation which is significantly influenced by fluid
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distribution, and reproduction in any mediumIndeed, a genetic predisposition can be observed in many
disorders associated with kidney stones, but cystinuria is
the only entity solely caused by genetic mutations. Among
adults cystine stones account for only 1-2% of all urinary
nephrolithiasis patients, but in children 6-8% of patients
suffer from cystine stones [3].
Cystinuria (OMIM 220100) is characterised by the
defective reabsorption of cystine, lysine, ornithine and
arginine in the brush border membrane of the proximal
renal tubule (S3 segment) and in the epithelial cells of
the gastrointestinal tract (for review: [4]). Although all
four amino acids reach high urinary concentrations, only
the resulting urinary hyperexcretion of cystine leads to
precipitation in the distal tubule and formation of cystine
stones due to its low solubility of at low pH. In patients
with large genomic deletions affecting the SLC3A1 gene
as well as at least the neighboured PREPL gene in 2p21,
urolithiasis is additionally associated with hypotonia and
further clinical symptoms (see below).
Clinical findings and classification
The first diagnosis of cystinuria is commonly based on the
finding of cystine stones which typically show characteristic
cystine crystals. The crystals are usually hexagonal,ntral Ltd. This is an Open Access article distributed under the terms of the
creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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pink or yellow in color, but later they turn to greenish due
to exposure to air. Cystine crystals are visible in 17 to 25%
of urine samples of patients with cystinuria (for review:
[2]). The stones may be identified by a positive nitroprus-
side cyanide test. Most stones are exceptionally formed of
cystine, but mixed composition can be observed. The diag-
nosis can be confirmed by determination of the urinary
amino acid excretion: in case of cystinuria urinary cystine
excretion is typically increased to >1000 μmoL/g creatin-
ine [5]. However, due to the incomplete expression of the
renal amino acid transporters a so-called transient neo-
natal cystinuria can be observed in cystinuria heterozy-
gotes, thus diagnosis before the 4 year of life should be
made with caution. [6].
Due to their composition, fragmentation of cystine
stones by extracoporal lithothripsy is often difficult, and
larger stones generally require percutaneous nephrostomy
placement and removed. Episodic stone symptoms make
repeated removements of the stones necessary. Indeed,
the disorder cause serious damage to the kidneys and
surrounding organs, and in some rare cases death if not
treated properly. Current treatment of cystinolithiasis is
currently focused on prevention of stone formation by
reducing cystine excretion and concentration and by redu-
cing cystine to the more soluble cysteine (for review: [4]).
However, causative therapies have not yet been developed
despite the growing knowledge on the physiological
aetiology of the disease.
For clinical purposes, the classification of cystinuria is
based on the urinary phenotype of obligate heterozygotes
(i.e. parents of patients with a classical course of cystinuria)
and three types of cystinuria have been distinguished [7,8].
Whereas type I heterozygotes excrete cystine at normal
levels, type II and III heterozygotes show a highly or
moderately elevated excretion. However, after the identifi-
cation of the genetic mutations predisposing to cystinuria,
a correlation between the extent of hyperaminoaciduria
and the mutation in type II/III heterozygotes could not
be established. Therefore both types II and III were
summarized as non-type I [9]. Non-type I heterozygotes
show a variable urinary hyperexcretion of cystine and the
dibasic amino acids, in some carriers stone formation has
been reported [10]. As a result, non-type I cystinuria
can be regarded as an autosomal-dominant disorder with
incomplete penetrance for cystine lithiasis, whereas type I
cystinuria mainly follow an autosomal-recessive trait. In
addition, patients with a mixed cystinuria have been
reported, carrying both type I and non-type I alleles (for
review: [4]).
In the majority of cystinuria patients, stone formation
occurs within the first two decades of life [11] but a
broad intrafamilial variation of the disease has been
reported. Males are affected more frequently andseverely than females, and males have a larger number of
stones. More than 80% of patients develop their first
stones within the first two decades, but stones may be
formed at any age. In male patients an earlier stone
formation can be observed in comparison to females.
Around 6% of patients do not form stones [12].
Goodyer et al. [5] observed a preponderance of an early
manifestation of stone formation in type I-homozygous
patients, whereas non-type I homozygous as well as mixed
type patients developed stones later in life. However, this
correlation could not be confirmed in molecularly proven
patients [13].
Frequency
Cystinuria is a global disorder with population-specific
prevalences, its overall prevalence has been estimated as
1:7000 in neonates [14]. It varies between different popula-
tions: the highest frequency has been observed among
Libyan Jews with a rate of 1:2,500, in Americans the rate is
1:15,000, and in Sweden 1:100,000 [14,15]. In specific
populations it can therefore be regarded as one of the
most common autosomal-recessive disorders comparable
only to cystic fibrosis. However, due to this limited infor-
mation about the prevalence of cystinuria in the general
population and the broad spectrum of mutations, the
frequency of cystinuria carriers can only be estimated. The
highest carrier rate of 1:25 in Libyan Jews has been identi-
fied by Sidi et al. [16]. In the Swedish population,
p.Met467Thr occurs in 0.5% of the general population [17].
The SLC3A1 and SLC7A9 genes and the amino acid
transporter system b0,+
The involvement of the SLC3A1 (OMIM 104614) gene in
the aetiology of cystinuria could be established in 1994 by
establishing linkage of the disease to 2p and by identifying
the first mutations in cystinuria patients [18,19]. Further
genetic linkage studies indicated that not all cystinuria
families were caused by SLC3A1 defects, and the second
cystinuria gene could be localised to chromosome 19q13
[20,21]. In 1999, first mutations in the SLC7A9 (OMIM
604144) gene were reported [9].
The SLC3A1 gene spans ~46 kb and includes 10
coding exons [22,23]. The longest transcript
(ENST00000260649) is 2989 bp long, the resulting pro-
tein rBAT (ENSP00000260649) consists of 685 amino
acids. The SLC7A9 gene comprises 12 exons, 11 of which
are coding. The transcript (ENST00000023064) has
1772 bp, the protein b0,+AT consists of 487 amino acids.
The two genes encode the two subunits of the renal
heteromeric amino acid transporter b0,+: the heavy subunit
rBAT (SLC3A1) and the light subunit b0,+AT (SLC7A9))
(Figure 1)(for review: [4]), both linked by a conserved di-
sulfide bridge. The heavy subunit mediates the localisation
of the holotransporter to the plasma membrane whereas
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transporter.
The rBAT/b0,+ amino acid transporter is expressed in the
apical membrane of the epithelial cells of the S1-S2 seg-
ments of the proximal tubule and of the small intestine. Via
the heterodimeric transporter the dibasic amino acids and
cystine are exchanged for other neutral amino acids in a 1:1
stochiometry. rBAT/b0,+AT represents the main mechan-
ism of tubular cystine transport and accounts for >90% of
renal cystine absorption.
As a result of its biological functions, mutations in
SLC3A1/rBAT have strong trafficking effects, either by a
deficient to assemble with b0,+AT or by failure to oligomer-
ize with subsequent degradation(for review: [4]). b0,+AT
mutations cause a loss of function of the transporter system
by defective folding, trafficking, heterodimerization, trans-
port activity or substrate recognition (for review: [4]).
Genetics and spectrum of mutations
As aforementioned, the classification of cystinuria was
historically based on the urinary excretion pattern of
heterozygotes. After identification of the molecular basis
of the disease a new classification was suggested: the
autosomal recessively inherited type I cystinuria which is
mainly caused by SLC3A1 mutations, and the incomplete
autosomal dominant non-type I cystinuria associated with
SLC7A9 variants. However, the identification of both
SLC3A1 mutations causing non-type I cystinuria and re-
cessive SLC7A9 mutations lead to a new strictly molecular
classification [11] which does not include the biochemical
phenotype: type A cystinuria represents SLC3A1 muta-
tions, and type B cystinuria includes SLC7A9 mutations.
Thus, three genotypes can be delineated: AA, BB, and the
mixed cystinuria AB.Figure 1 Cellular localisation and function of rBAT (SLC3A1) and b0,+AIn large screening studies, more than 130 pathogenic var-
iants in SLC3A1 and nearly 100 mutations in SLC7A9 have
been reported (for review: [4,24]). The observed variants
cover the whole spectrum of mutations, ranging from non-
sense, missense, splicing, and frameshift mutations to whole
and multi-exon imbalances. The significant role of large
genomic rearrangements became obvious with the identifi-
cation of the first deletions/duplications in SLC3A1 [25] and
the characterisation of the relatively frequent duplication
affecting exons 5 to 9 (dupE5E9; c.891+1524_1618-
1600dup) in SLC3A1 [4,24] accounting for at least 11% of
mutated SLC3A1 alleles (Table 1). A systematic screen for
whole exon/multi exon imbalances was recently reported
by Bisceglia et al. [24] applying MLPA (multiplex ligation
probe-dependend amplification): they could demonstrate
that large rearrangements significantly contribute to the
spectrum of mutations in both cystinuria genes in Italy.
In single patients, three pathogenic mutations can be
detected [27,31]. Indeed, the identification of three recessive
variants in the same gene is a rare finding but it is a well
known observation also from other autosomal recessive
disorders, e.g. cystic fibrosis or autosomal recessive polycys-
tic kidney disease. This means that at least two mutations
are localised on the same allele, and this might lead to false-
positive or false-negative results in carrier diagnostics.
SLC3A1
As mentioned before, mutations in SLC3A1 are gener-
ally associated with type I cystinuria, but with the
dupE5E9 exceptions exist [10]; heterozygote carriers of
this mutations show an increased urinary cystine excre-
tion pattern.
Mutations are distributed over the whole gene, affecting
all exons and all functional domains (Figure 2). AmongT (SLC7A9).
Table 1 Overview on the most frequent cystinuria mutations in a) SLC3A1, and b) SLC7A9 in different ethnic groups
a) SLC3A1
Cohort Cohort
size
(n)°
p.Tyr151Cys/
Asn*
p.Thr216Met p.Arg270X/
Leu*
p.Arg362Cys/
His*
p.Arg365Gln/
Trp/Leu/Pro*
p.Arg452Trp/
X*
p.Met467Thr p.Met467Lys p.Ser547Trp/
Lys*
dupE5E9 Identified
Alleles
Methods References
Exon 2 3 4 6 6 8 8 8 10 5-9
Europe
Czech/
Slovakia
24 0 5 0 0 1 3 12 0 1 ND 29 sequencing [26]
Germany 75 0 7 1 1 5 1 19 0 2 13 69 sequencing,
qPCR
[25,27-30]
Greece 20 0 9 2 0 1 0 4 0 0 ND 21 SSCP, RFLP [31]
4 0 8 0 0 0 0 0 0 0 ND 8 sequencing [25,27,28,
30,32]
Italy 168 2 10 1 5 5 4 34 7 9 11 145 sequencing,
MLPA
[24]
12 0 1 0 0 1 0 1 2 0 0 5 sequencing,
qPCR
[25,27,28,
30,32]
Poland 9 0 1 0 0 0 1 1 0 0 2 5 sequencing,
qPCR
[29]
Portugal 12 0 0 0 0 0 0 2 0 0 4 13 sequencing,
MLPA, RNA
[33]
Sweden 43 8 0 0 1 0 0 43 0 1 ND 53 SSCP [34]
Spain 142 0 2 0 1 2 2 12 0 0 0 63 sequencing,
MLPA
[35], for
review:
[4]
former
Yugoslavia
13 0 15 0 0 2 0 2 0 0 0 8 sequencing,
qPCR
[25,27,
28,30,32]
Asia
China 8 0 0 0 0 2 0 0 0 1 ND 6 sequencing [37]
Israel 5 0 0 10 0 0 0 0 0 0 ND 10 cDNA
sequencing
[18]
Japan 36 0 0 0 0 0 0 0 0 0 ND 8 RNA SSCP [38]
Turkey 24 ND ND ND ND ND ND 4 2 ND ND 6 RFLP [39]
Turkey 17 0 6 0 0 0 0 1 0 0 9 seqencing,
qPCR
[25,27,28,
30,32]
North
America
Canada
(French)
20 0 2 1 0 0 0 2 0 0 ND 16 RNA
Mismatch
[40]
USA
(Texas)
33 0 0 4 0 0 1 12 0 0 ND 34 SSCPRNA
MistMatch
[41]
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Table 1 Overview on the most frequent cystinuria mutations in a) SLC3A1, and b) SLC7A9 in different ethnic groups (Continued)
Total 10 66 19 8 19 12 149 11 14 30 508
Ratio of
known
alleles (%)
1.9 13.0 3.7 1.6 3.7 2.4 29.3 2.2 2.6 11.1
b) SLC7A9
Cohort Cohort
size(n)°
p.Gly105Arg p.Thr123Met p.Val170Met p.Ala182Thr p.Glu244del p.Ala331Val p.Arg333Trp/
Gln
p.Pro482Leu c.614dupA Identified
Alleles
Methods References
Exon 4 4 5 5 7 10 10 13 6
Europe
Czech/
Slovakia
24 3 2 0 0 0 0 0 0 1 11 sequencing [26]
Germany 75 10 0 0 2 1 1 3 0 1 32 sequencing,
qPCR
Greece 20 11 0 0 0 0 0 4 0 0 22 SSCP, RFLP [31]
4 0 0 0 0 0 0 0 0 0 0 sequencing [25,27,
28,30,32]
Italy 168 44 1 0 7 4 0 18 1 2 163 sequencing,
MLPA
[24]
12 2 0 0 0 1 0 1 0 0 6 sequencing,
qPCR
[25,27,
28,30,32]
Poland 9 0 0 0 0 0 0 0 0 0 1 sequencing,
qPCR
[29]
Portugal 12 0 0 0 0 0 0 0 0 1 8 sequencing,
MLPA, RNA
[33]
Sweden 15 0 0 0 1 0 0 0 0 0 1 SSCP [17]
Spain 142 14 9 0 4 1 0 20 0 21 72 sequencing,,
MLPA, SSCP
[for review: 4]
former
Yugoslavia
13 1 0 0 0 0 0 0 0 0 3 sequencing,
qPCR
[25,27,
28,30,32]
Asia
China 8 0 0 0 0 0 0 0 0 0 7 sequencing [35]
Israel,
Libyan
8 ND ND 16 ND ND ND ND ND ND 16 cDNA
sequencing
[16]
Japan 39 0 0 0 0 0 0 3 56 66 RNA SSCP [42]
Turkey 17 1 0 0 0 0 4 0 0 0 12 seqencing,
qPCR
[25,27,28,30,32]
13 0 0 0 0 0 0 0 0 1 5 SSCP [35]
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Table 1 Overview on the most frequent cystinuria mutations in a) SLC3A1, and b) SLC7A9 in different ethnic groups (Continued)
North
America
Canada
(French)
Total 86 12 16 14 7 5 49 57 27 425
Ratio of
known
alleles
20.2 2.8 3.8 3.3 1.6 1.2 11.5 13.4 6.4
(frequent mutations or population specific frequencies are printed in bold face. ° total number of patients screened in this study, including classified and unclas d patients * different basepair substitutions have
been reported affecting the same codon. # only single study cohorts were screened for this variant, here the total number of alleles is 271; RFLP restriction fragm t length polymorphism; qPCR quantitative PCR, SSCP
single strand conformation polymorphism analysis, ND not determined).
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TMD          
AA88-110
11 9 9 6 5 13 6 16 8 29
p.Tyr151Cys p.Thr216Met Arg270X
p.Arg365Thr/Trp/Leu/Pro
p.Arg452Trp/X
p.Met467Thr/Lys
p.Ser547Trp/Lys
p.Arg362Cys/His
a
SLC3A1/rBAT
TMD
30-
52
TMD
110-
132
TMD
67-
89
TMD
147-
169
TMD
176-
198
TMD
252
TMD
213 -
232 274
-
TMD
377-
396
TMD
345-
367
TMD
303-
325
TMD
409-
431
TMD
435-
457
1 14 17 12 7 5 8 5 8 3 9 2
p.Gly105A
p.Thr213Met
p.Ala182Thr
p.Val170Metc.614dup
p.Glu244del
p.Arg333Trp/Gln
p.Pro482Leup.Ala331V
b
SLC7A9/b0,+AT
Figure 2 Genomic structure and putative function of the encoded protein regions of the cystinuria genes: the total number of
mutations described so far for each exon is shown above, the localisation of the most frequent mutations is shown below the exon
structure. a) SLC3A1/rBAT (TMD transmembrane domain; the largest part of the protein consists of an ectodomain (light brown) of three domains
A-C, for further details see [4]). b) SLC7A9/b0,+AT (TMD transmembrane domain).
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generally the most frequent one, accounting for ~30% of
the known SLC3A1 alleles and detectable in nearly all
ethnic groups (Table 1).The amino acid substitution p.Thr216Met in exon 3 is
the second frequent variant (~13% of all identified SLC3A1
alleles), but it shows a preponderance in patients from
South-Eastern Europe (for review: [4,25]) and thus reflects
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cystinuria mutations.
For some variants an ethnic influence can be observed:
it is mostly obvious for the mutation p.Arg270X which
has been identified in 73% of Ashkenazi Jewish patients
and accounts for 11% of the known SLC3A1 mutations
in North America (Table 1). The mutation p.Tyr151Cys
has mainly been observed in Northern Europe [34]. The
duplication dupE5E9 might have occurred from a
German founder, however data are limited as tests
aiming on larger genomic imbalances were not routinely
applied for cystinuria diagnostics in the past.
SLC7A9
The functional consequences of SLC7A9 mutations are
generally broader than that in SLC3A1. For many SLC7A9
mutations, an autosomal-dominant influence can be
observed in respect to the urinary amino acid patterns, but
the penetrance is incomplete in respect to stone fomation.
As a result, a genotype-phenotype correlation is merely
possible and a broad intrafamilial biochemical and clin-
ical spectrum for the same mutation can be observed.
Similar to SLC3A1, mutations in SLC7A9 can be
detected in all exons of the gene (Figure 1) but there
are hot spots for mutations in exons 3, 4, 5 and 6
(Table 1). Among the SLC7A9 mutations, the amino
acid substitution p.Gly105Arg accounts for approxi-
mately 20% of identified alleles and is present in nearly
all ethnic groups.
The second frequent mutation p.Arg333Trp is also
detectable worldwide, whereas other variants are often
rare. Interestingly, three mutations show a strong ethnic
association: p.Val170Met is restricted to Libyan Jews
where it accounts for all patients; p.Pro482Leu affects
>84% of the identified SLC7A9 alleles in the Japanese
cystinuria cohort [42]. The duplication c.614dupA is
preponderant in Spanish patients, accounting for 29% of
SLC7A9 alleles and probably originating from a founder
in Asturias (for review: [4]).
In the group of rare SLC7A9 mutation, the variant p.
Thr123Met should be mentioned separately as it illustrates
the broad physiological and clinical phenotype of SLC7A9
mutations. The amino acid excretion patterns can range
from nearly normal to isolated cystinuria to hyperexcretion
of cystine and the dibasic amino acids in carriers of
p.Thr123Met [10,43].
The hypotonia-cystinuria syndrome and 2p21
microdeletions
Larger deletions affecting SLC3A1 might result in the
so-called hypotonia-cystinuria syndrome (HCS; OMIM
606407). This autosomal recessive congenital disorder is
associated with deletions of at least the SLC3A1 and
PREPL genes on chromosome 2p21. The main clinicalfeatures include a generalised hypotonia at birth, failure
to thrive, growth retardation and cystinuria. Meanwhile
13 patients with HCS have been reported, all were
homozygous for deletions in 2p21 [44,45]. So far, five
different HCS deletions have been identfied, two of them
(deletions “A” and “B”) were found to be globally distributed.
Despite their different sizes ranging from ~38 to ~127 kb,
they all affect (at least in parts) the SLC3A1 and PREPL
genes resulting in functionally homozygous deletions of
both genes. A further patient with cystinuria as the only
clinical feature was detected by screening cystinuria
patients for SLC3A1 mutations; the patient was compound
heterozygous for a SLC3A1/PREPL deletion and a deletion
in SLC3A1 affecting exons 1 to 7 [40]. In contrast to the
association of SLC3A1 mutations with cystinuria, variants
restricted to PREPL causing an “isolated hypotonia”
phenotype have not yet been reported. Nevertheless, it
has been postulated that the phenotype in HCS patients
can be attributed to the lack of PREPL, a putative serine
oligopeptidase with a currently unknown physiological
function [44].
A second microdeletion syndrome also affecting 2p21
but larger in size (~179 kb) is referred to as 2p21 deletion
syndrome [46]. This deletion has been detected in a large
Bedouin pedigree. Homozygous deletion carriers in this
family showed HCS and additional features including
neonatal seizures and a severe global retardation, indicat-
ing that the loss of a third gene in 2p21, PPM1B, also
contributes to the clinical spectrum in this family. Mean-
while, additional patients with an intermediate phenotype
between HCS and the 2p21 microdeletion syndrome and
deletions intermediate in size have been described [47].Further cystinuria candidate genes
Considering the observation that in many studies the
detection rates for mutations in SLC3A1 or SLC7A9 do
no reach 100% and due to the complex nature of renal
amino acid transport, the role of further genes and modi-
fying factors in the etiology of cystinuria have been postu-
lated. However, linkage analyses in cystinuria families
did not indicate the existence of more than two cysti-
nuria loci, 2p21 (SLC3A1) and 19q13 (SLC7A9), there-
fore the localisation of further genes encoding amino
acid transporter subunits within this region was
conceivable.
One candidate in 19q13 was SLC7A10 (ASC-1) which
shows high homology with SLC7A9 but several studies
excluded pathogenic mutations in this gene [31,48-50].
The neutral amino acid transporter system ATB(0)
(SLC1A5) is also localised in 19q13, but mutation ana-
lysis in cystinuria families with possible linkage to this
region did not provide evidence for a contribution of
SLC1A5 mutations to the clinical course [32].
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explained by the physiological dominance of some SLC7A9
alleles, in these cases a second mutation is not needed
to influence the phenotype. Furthermore, it has been
suggested that at first glance apathogenic single nucleotide
polymorphisms (SNPs) might predispose a cystinuria
phenotype in case of co-occurrence with other mutations
[28,51] and might serve as modifiers.
Genetic testing strategies for cystinuria
The developing of genetic tests for cystinuria reflects
the rapid technological evolution in the last two dec-
ades. Molecular genetic testing was firstly established
after the identification of the rBAT cDNA and first
mutations in 1994. At that time the genomic structure
of SLC3A1 was not known and single PCRs with subse-
quent restriction digests were established for specific
mutations. With the characterisation of the genomic
structure of both genes, unspecific screening methods
like SSCP (single strand conformation polymorphism
analysis) were applied to screen large cohorts of patients.
However, these tests were limited due to their sensitivity
and reproducibility, therefore Sanger sequencing became
the gold standard for molecular genetic analysis in cysti-
nuria. To circumvent the problem that large rearrange-
ments not covered by conventional sequencing approaches
might escape detection, several quantitative assays, i.e.
quantitative PCR and multiplex ligation probe-dependent
amplificiation (qPCR and MLPA), have been implemented
in diagnostic algorithms.
Based on the growing knowledge on the genetic and
biochemical basis of cystinuria, the following aspects
should be considered prior to molecular genetic testing:
- biochemical and clinical data might influence the
diagnostic algorithm: in the majority of cases, patients are
referred with the clinical diagnosis of urolithiasis. In this
situation the careful family history and urinary amino acid
excretion patterns from the parents might help to decide
which gene should be tested first: in case of sporadic
occurrence and normal parental urinary amino acid
excretion, SLC3A1 should be tested, in case of a positive
family history and parental hyperaminoaciduria, SLC7A9
testing should be prioritized. However consanguinity
might mimic an autosomal recessive inheritance and
mutations in both genes show a broad observable range of
urinary cystine excretion. Furthermore, the
comprehensive data are often difficult to obtain or
information of family members are not available.
- ethnic origin: for specific populations (e.g. Japan,
Sweden, South-East Europe, Spain) a targeted algorithm
can be applied as these groups show specific mutations.- testing procedure: Frequent or population-specific
mutations might be tested by targeted genotyping
approaches (e.g. restriction assays). In case of
sequencing of the coding regions and the intron/exon
boundaries, one might consider to start with the “hot
spot” exons harbouring multiple mutations and
frequent variants (e.g. exon 8 of SLC3A1, exon 4 of
SLC7A9). In case none of these frequent mutations is
detectable, the total coding sequences of both genes
have to be sequenced. After exclusion of exonic
mutations, quantitative tests should follow as intragenic
duplications/deletions significantly contribute to the
spectrum of mutations in cystinuria [24]. In case of
unusual phenotypes, molecular karyotyping with DNA
microarrays is an appropriate tool to identify large
genomic imbalances as reported for the HCS [44]. This
step-wise analysis can be stopped after identification of
two pathogenic variants explaining the clinical course
of the patient, although the presence of a third
mutation [27,31] can not be excluded.Cystinuria and genetic counselling
In contrast to other disorders characterised by urolithiasis,
cystinuria is solely caused by genomic mutations. Never-
theless, the interpretation of the molecular results and
genetic counselling in cystinuria families is often compli-
cated by the difficulty to differentiate between patients and
heterozygote carriers of mutations with ambiguous clinical
significance. In these situations, a prediction of the clinical
course or a targeted therapeutic regime is often asked by
the patients and their families. However, an unambiguous
prognosis is merely possible due to the broad clinical
variability even in carriers of the same mutation and the
influence of so far unknown modifying endo- and exogen-
ous factors. Nevertheless, a more-directed counselling has
become possible based on the molecular classification
suggested by DelloStrologo et al. [11]:- AA (homozygosity for one or compound
heterozygosity for two SLC3A1 mutations) is mainly
consistent with an autosomal recessive inheritance of
cystinuria. The parents are obligate carriers but with a
normal renal cystine excretion, a recurrence risk of 25%
can be delineated for children to be affected by
cystinuria. However, there is evidence at least the
mutation dupE5E9 is associated with non-type I
cystinuria, i.e. carriers show an increased cystine
excretion [10]. Heterozygote carriers of this variant
should be tested for urinary cystine excretion.
- A? (heterozygosity for a SLC3A1 mutation, a second
mutation could not be identified): probably a second
mutation in one of the two genes is present but not
Eggermann et al. Orphanet Journal of Rare Diseases 2012, 7:19 Page 10 of 11
http://www.ojrd.com/content/7/1/19detectable by the applied methods. However, in the case of
clinical diagnosis of cystinuria, the identification of only
one mutation in SLC3A1 should be sufficient for
confirmation. To further estimate the recurrence risk in
these families the urinary excretion patterns and the
cystinuria genotype of the parents should be determined.
In case of a normal cystine excretion in that parent not
contributing the SLC3A1 mutation compound
heterozygosity for the identified and an unknown SLC3A1
mutation can be delineated for the patient. If the parent
not carrying the detected SLC3A1 mutation shows an
increased cystine excretion, a SLC7A9 mutation can be
assumed. In that case the clinical prediction for the
offspring expected to be heterozygous for the (unknown)
SLC7A9 mutations is difficult because of the broad range
of biochemical penetrance of mutations in this gene.
- BB (homozygosity for one or compound
heterozygosity for two SLC7A9 mutations) is consistent
with cystinuria. The recurrence risk for sibs is at least
25%, but due to the possible dominant nature of
SLC7A9 mutation and the broad ranges of urinary
amino acid excretion even in the same family the risk
to develop cystine stones is higher. Here the
biochemical analysis of the urine of heterozygote
mutation carriers and the knowledge of the pathogenic
nature of the mutation might help to further delineate
the risk to develop stones.
- B? (heterozygosity for a SLC7A9 mutation, a second
mutation could not be identified): this finding is the most
difficult one to interpret: as discussed for the BB
genotype, the same mutation might behave recessive in
one generation and dominant in another in the same
family. Thus the identification of just one SLC7A9
mutation might be compatible with an extremely
increased cystine excretion, the prognosis in newborns or
children is merely possible.
- AB (mixed heterozygosity of a SLC3A1 and a SLC7A9
mutation): this finding explains the clinical phenotype,
but as discussed for the A?, BB and the B? genotypes,
the probable dominant effect of a SLC7A9 mutation has
to be bare in mind in genetic counselling.
- AAA/AAB/ABB (three SLC3A1/SLC7A9 mutations
in one patient): this rare finding explains the phenotype,
but the parents should be checked for the mutations to
identify the chromosome harbouring two mutations
and thereby to avoid false-negative carrier testing
results in the further family.
In clinical practice, the molecular genetic testing results
only scarcely influence the prognosis and therapy ofcystinuria as causative therapies do currently not exist.
Indeed, more than 95% of all carriers of two SLC3A1 or
SLC7A9 mutations (genotypes AA, BB, AB) will develop
kidney stones in their live but the age of kidney stone for-
mation is difficult to predict and shows a broad intrafami-
lial variability. Furthermore, the urinary excretion pattern
in heterozygote SLC7A9 mutation carriers is extremely
variable and does therefore hardly allow a prediction of
the clinical course whereas the majority of SLC3A1
heterozygotes do not exhibit a biochemical phenotype (for
review: [12]). As far as the comprehensive knowledge on
the pathophysiology of cystinuria can not be applied in a
causative therapy, the biochemical determination of the
urinary cystine excretion pattern remains the basic tool for
prognosis and therapeutic management of cystinuria.
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